[ad_1] Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. SAN FRANCISCO — Investors…
[ad_1] Merck receives positive EU CHMP opinion for expanded use of Winrevair in adults with Pulmonary Arterial Hypertension We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Merck division gets USFDA conditional approval for Exzolt Cattle-CA1 against cattle fever tick We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Merck bags European Commission nod for subcutaneous administration of Keytruda for all adult indications approved in EU We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Merck to acquire Cidara Therapeutics for USD 9.2 billion We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Merck said Friday it would buy Cidara Therapeutics, the maker of an experimental flu therapy, in a $9.2 billion deal, as the pharma giants widens its pipeline to counter the impending revenue hit as its…
[ad_1] Merck inks pact with Dr Falk Pharma for certain development, commercialization rights to MK 8690 We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Merck enters into RnD funding agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A pill designed to further lower cholesterol in people already on statins but at risk of a serious cardiovascular event — their first or a recurrence — reduced…
[ad_1] Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. BERLIN — At a primetime session on Saturday at a major cancer conference here, researchers reported such dramatic benefits of a bladder cancer treatment — driven in part by Merck’s Keytruda — that the audience of doctors…